VBLT Short Information, Vascular Biogenics Ltd.

Twenty Trading Day Totals
Total Shorted Volume	6,222,401
Total Actual Volume	41,630,929

Averages
Average Short Volume	311,120
Average Short Percentage	46.62%

Is there a VBLT Short Squeeze or Breakout about to happen?

See the VBLT Short Analysis for free Sign up or Login

Stock Date	Open Price	Close Price	High	Low	Total Volume	Short Volume	Short Percentage
2021-02-23	2.73	2.06	3.17	1.92	27,101,798	3,821,986	39.8158
2021-02-22	2.77	2.23	2.83	2.21	2,520,194	282,013	46.4549
2021-02-19	2.48	2.55	2.55	2.47	252,840	43,680	37.8828
2021-02-18	2.45	2.51	2.51	2.38	515,111	89,588	51.9074
2021-02-17	2.57	2.52	2.57	2.4612	297,011	57,021	48.0428
2021-02-16	2.63	2.58	2.717	2.55	540,287	132,654	57.6661
2021-02-12	2.51	2.55	2.55	2.4263	314,559	38,814	36.9365
2021-02-11	2.62	2.52	2.64	2.35	524,909	142,532	66.6283
2021-02-10	2.33	2.6	2.64	2.33	1,226,149	115,179	21.3997
2021-02-09	2.53	2.31	2.5819	2.17	2,002,315	316,412	45.4854
2021-02-08	2.5	2.46	2.58	2.41	843,166	104,812	41.6031
2021-02-05	2.35	2.39	2.43	2.25	465,632	127,173	55.2527
2021-02-04	2.35	2.33	2.35	2.19	675,143	119,359	51.5254
2021-02-03	2.38	2.29	2.4049	2.21	616,717	77,496	32.3384
2021-02-02	2.5	2.39	2.5	2.32	296,083	49,023	59.5496
2021-02-01	2.51	2.44	2.56	2.37	441,489	104,920	43.2068
2021-01-29	2.43	2.49	2.59	2.31	687,724	89,825	50.6973
2021-01-28	2.62	2.52	2.69	2.35	562,237	188,751	67.5210
2021-01-27	2.81	2.63	2.81	2.51	637,040	61,630	24.4730
2021-01-26	2.96	2.72	3.04	2.62	1,110,525	259,533	54.0226

Stock Information

Vascular Biogenics Ltd. Company Name:

VBLT Stock Symbol:

NASDAQ Market:

Get VBLT Alerts

News, Short Squeeze, Breakout and More Instantly...

VBLT - VBL Therapeutics Announces Data Safety Monitoring Committee Provides Green Light to Advance the OVAL Phase 3 Registration Enabling Study of VB-111 in Ovarian Cancer

TEL AVIV, Israel, Feb. 22, 2021 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT) today announced the results of the independent Data Safety Monitoring Committee (DSMC) pre-planned review of the ongoing OVAL Phase 3 registration enabling study of VB-111 in recurrent ovarian cancer. The co...
VBLT - VBL Therapeutics Treats First Patient in Phase 2 Randomized Controlled Study of VB-201 in COVID-19 Patients

TEL AVIV, Israel, Jan. 27, 2021 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT) today announced the dosing of the first patient in a randomized controlled Phase 2 study of the Company’s proprietary investigational oral immune-modulator molecule, VB-201 for the treatment of COVID-...
VBLT - VBL Therapeutics Enters Into Ordinary Share Purchase Agreement of up to $20 Million With Aspire Capital Fund, LLC

TEL AVIV, Israel, Jan. 15, 2021 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT), a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of first-in-class treatments for areas of unmet need in cancer and immune/inflammatory indications, tod...